-
The bispecific molecular targeted drug “YY0411”
that is being developed by our company
as a specific pharmaceutical for lung cancer was
appraised as an innovative treatment
that would significantly
reform lung cancer treatment.It was featured in the international
academic journal “nature”
titled “ADVERTISEMENT FEATURE”,
issued on April 19th.